363 Results

Three-year overall survival (OS) results from the Phase III PACIFIC trial of Imfinzi for Stage III non-small cell lung cancer.

 Added 16 days ago

AstraZeneca has presented three-year overall survival (OS) results from the Phase III PACIFIC trial of Imfinzi (durvalumab) in unresectable, Stage...

Five-year results from KEYNOTE-001 shows Keytruda response in longest follow-up trial for NSCLC.

 Added 17 days ago

Merck Inc announced the presentation of five-year efficacy and safety data for Keytruda (pembrolizumab) as monotherapy in patients with advanced...

FDA expands approval of PD-L1 IHC 22C3 pharmDx assay in NSCLC

 Added 2 months ago

Agilent Technologies announced that the FDA has updated its approval of the company’s PD-L1 IHC 22C3 pharmDx assay. The assay...

FDA approves extension of label for Keytruda for the first-line treatment of patients with stage III NSCLC

 Added 2 months ago

Merck Inc. announced that the FDA has approved an expanded label for Keytruda Merck’s anti-PD-1 therapy, as monotherapy for the...

BMS provides long-term survival results from pooled analyses of Opdivo in previously-treated NSCLC patients

 Added 2 months ago

Bristol-Myers Squibb Company announced results from pooled analyses of survival data from four studies...

NICE recommends Imfinzi for patients with locally advanced unresectable NSCLC

 Added 2 months ago

The National Institute for Health and Care Excellence ( NICE) has recommended, Imfinzi (durvalumab) from AstraZeneca in a small subgroup...

FDA approves Tecentriq, chemotherapy and epotoside to treat small cell lung cancer

 Added 2 months ago

Genentech, a member of the Roche Group announced that the FDA approved Tecentriq (atezolizumab), in combination with carboplatin and etoposide...

Phase III KEYNOTE-407 trial of Keytruda in combination with chemotherapy leads to first line EU approval for NSCLC

 Added 3 months ago

First line EU approval is based on data from the Phase III KEYNOTE-407 trial which demonstrated that Keytruda in combination...

Phase III results positive for Cymraza + erlotinib in first line NSCLC/EGFR

 Added 3 months ago

Eli Lilly and Company announced that its Phase III RELAY study of Cymraza (ramucirumab) met its primary endpoint of progression-free...

European Commission approves Tecentriq + Avastin and chemotherapy for the initial treatment of specific types of metastatic lung cancer

 Added 3 months ago

Roche has announced that the European Commission has approved and granted marketing authorisation for Tecentriq (atezolizumab) in combination with Avastin...

Load more